Search
Search titles only
By:
Search titles only
By:
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Forums
New posts
All threads
Latest threads
New posts
Trending threads
Trending
Search forums
What's new
New posts
New ads
New profile posts
Latest activity
Free Ads
Latest reviews
Search ads
Members
Current visitors
New profile posts
Search profile posts
Contact us
Latest ads
🚀 Google AI PRO – 18 Months | Rs. 850 Only
lkkolla
Updated:
Yesterday at 4:56 PM
🔒 NordVPN Premium – 3 Months
hrdilshan
Updated:
Thursday at 8:29 PM
🚀 Microsoft Office 365 Pro Plus – Lifetime Access! 🚀
hrdilshan
Updated:
Thursday at 8:28 PM
Linkedin Premium Business / Careere /Sales Navigator - 1/2/3/6/9/12 Months - Reddem Link
hrdilshan
Updated:
Thursday at 8:27 PM
Colombo
YEYE 3 in 1 Instant Coffee Mix 50 Sachet
Romeshka
Updated:
Wednesday at 12:16 AM
Electronics
Vehicles
Property
Search
Reply to thread
Forums
General
ElaKiri Talk!
Merck's new pill cuts "Bad" Cholesterol by 60%
Get the App
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="imhotep" data-source="post: 31299455" data-attributes="member: 562115"><p>A new experimental medication called <strong>Enlicitide </strong>has shown powerful cholesterol-lowering effects in a large clinical study. In a phase three trial reported in The NEJM, the once-daily pill reduced levels of low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, by as much as 60%.</p><p></p><p>Scientists have long recognized that LDL cholesterol plays a central role in cardiovascular disease. These cholesterol-carrying particles can accumulate within the walls of blood vessels, gradually forming fatty deposits known as plaques. This process, called atherosclerosis, can narrow arteries and eventually trigger heart attacks or strokes. Because of this link, reducing LDL cholesterol remains one of the most important strategies for preventing cardiovascular disease and lowering risk in people who already have it.</p><p></p><p>Decades of research work is behind this discovery and the science behind <strong>Enlicitide</strong> traces back to foundational research carried out at UT Southwestern. Several decades ago, Michael Brown, M.D., Professor of Molecular Genetics and Internal Medicine, and Joseph Goldstein, M.D., Chair and Professor of Molecular Genetics and Professor of Internal Medicine, identified the LDL receptor on liver cells.</p><p></p><p>This receptor removes LDL cholesterol from the bloodstream. Their discovery earned the pair the Nobel Prize in Physiology or Medicine in 1985 and opened the door to the development of statins, which later became the most widely used medications for lowering cholesterol.</p><p></p><p>Enlicitide inhibits a liver protein called PCSK9 to clear out LDL cholesterol. This is not yet FDA approved.</p><p></p><p>Drugs like Lipitor, Crestor works by inhibiting HMG CoA reductase in the liver. While injectable PCSK9 inhibitor drugs like Evolocumab, Alirocumab, Inclisiran (siRNA - small interfering RNA) do exist these are expensive and only used in specific cases. The new Merck drug is oral and also said to be well tolerated.</p></blockquote><p></p>
[QUOTE="imhotep, post: 31299455, member: 562115"] A new experimental medication called [B]Enlicitide [/B]has shown powerful cholesterol-lowering effects in a large clinical study. In a phase three trial reported in The NEJM, the once-daily pill reduced levels of low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, by as much as 60%. Scientists have long recognized that LDL cholesterol plays a central role in cardiovascular disease. These cholesterol-carrying particles can accumulate within the walls of blood vessels, gradually forming fatty deposits known as plaques. This process, called atherosclerosis, can narrow arteries and eventually trigger heart attacks or strokes. Because of this link, reducing LDL cholesterol remains one of the most important strategies for preventing cardiovascular disease and lowering risk in people who already have it. Decades of research work is behind this discovery and the science behind [B]Enlicitide[/B] traces back to foundational research carried out at UT Southwestern. Several decades ago, Michael Brown, M.D., Professor of Molecular Genetics and Internal Medicine, and Joseph Goldstein, M.D., Chair and Professor of Molecular Genetics and Professor of Internal Medicine, identified the LDL receptor on liver cells. This receptor removes LDL cholesterol from the bloodstream. Their discovery earned the pair the Nobel Prize in Physiology or Medicine in 1985 and opened the door to the development of statins, which later became the most widely used medications for lowering cholesterol. Enlicitide inhibits a liver protein called PCSK9 to clear out LDL cholesterol. This is not yet FDA approved. Drugs like Lipitor, Crestor works by inhibiting HMG CoA reductase in the liver. While injectable PCSK9 inhibitor drugs like Evolocumab, Alirocumab, Inclisiran (siRNA - small interfering RNA) do exist these are expensive and only used in specific cases. The new Merck drug is oral and also said to be well tolerated. [/QUOTE]
Insert quotes…
Verification
Asuwa dahayen wadi kalama keeyada?
Post reply
Top
Bottom